NVS

Novartis AG Sponsored ADR · NYSE

Sector Health Technology
Industry Pharmaceuticals: Major
Website novartis.com
Employees(FY) 101703
ISIN US66987V1098

Performance

+5.48%

+8.41%

-4.0%

-5.73%

+8.43%

YTD

+5.24%

Profile

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Advanced Technical Analysis

Technical Analysis of NVS 2025-01-31

The stock exhibits a generally bullish sentiment with a Moving Average Score of 70 and a Technical Score of 69, indicating strong upward momentum, while the Oscillators Score of 50 suggests a neutral stance. Overall, the combination of these scores points to a favorable outlook for the stock, though caution may be warranted due to the neutral os...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NVS

Stock Rank

Recent News & Updates

2025-02-03 08:32
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond(Motley Fool)
2025-02-01 12:33
Analyst Report: Novartis AG(Morningstar Research)
2025-02-01 02:03
Novartis AG (NVS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Outlook ...(GuruFocus.com)
2025-01-31 16:08
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition(Investor's Business Daily)
2025-01-31 13:20
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain(Zacks)
2025-01-31 13:16
Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed(MT Newswires)
2025-01-31 13:00
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript(Motley Fool)
2025-01-31 09:30
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates(Zacks)
2025-01-31 08:44
Health Care Roundup: Market Talk(The Wall Street Journal)
2025-01-31 06:49
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb(BioPharma Dive)
2025-01-31 06:26
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries(Benzinga)
2025-01-31 05:10
Novartis: Q4 Earnings Snapshot(Associated Press Finance)
2025-01-31 04:40
Novartis Expects Further Profit, Sales Growth Despite Competition Threat(The Wall Street Journal)
2025-01-31 04:15
Novartis Q4 Core Earnings, Revenue Rise(MT Newswires)
2025-01-30 21:19
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker(Yahoo Finance)
2025-01-30 19:00
Chevron earnings, December PCE, FedSpeak: What to Watch(Yahoo Finance Video)
2025-01-30 12:14
Novartis handily beats Q4 earnings consensus(Yahoo Finance)
2025-01-30 12:00
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024(Yahoo Finance)
2025-01-28 13:38
Novartis to Report Q4 Earnings: What's in the Offing?(Zacks)
2025-01-28 06:43
Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says(BioPharma Dive)
2025-01-22 03:00
After an obesity stumble, BioAge reconnects with its longevity pipeline(Pharma Voice)
2025-01-17 09:15
Sector Update: Health Care Stocks Rise Premarket Friday(MT Newswires)
2025-01-17 07:27
Novartis Obtains Temporary Court Order Blocking Generic Version of Entresto(MT Newswires)
2025-01-16 16:07
US appeals court reinstates pause on generic version of Novartis' Entresto(Reuters)
2025-01-16 12:09
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug(Benzinga)
2025-01-16 03:56
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson(BioPharma Dive)
2025-01-15 19:01
Novartis wins temporary pause to Entresto generic launch in US(Reuters)
2025-01-14 16:57
JP Morgan 2025: Novartis streamlines its portfolio to drive future growth(Pharmaceutical Technology)
2025-01-13 13:00
Broader population could benefit from Novartis spinal muscular atrophy treatment(Clinical Trials Arena)
2025-01-12 12:15
Novartis Entresto® US patent upheld by US Court of Appeals(Yahoo Finance)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.